Affinia Therapeutics Welcomes Rami Daoud as Chief Business and Financial Officer
Affinia Therapeutics is proud to announce the appointment of Rami Daoud as the new Chief Business and Financial Officer. With a wealth of experience in the biotech industry, Daoud's role will focus on steering the company's financial strategies to bolster its strategic objectives.
This change comes at a pivotal time as Affinia continues to develop its proprietary platform aimed at delivering innovative gene therapies for both rare and common diseases. Daoud's insights and leadership are anticipated to significantly impact the direction of Affinia Therapeutics.
About Affinia Therapeutics
Affinia Therapeutics is dedicated to creating rationally-designed gene therapies that target a range of devastating diseases. The company is leading the charge toward enhanced therapeutic options that promise to transform patient outcomes in the medical field.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.